Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
4DMedical Ltd ( (AU:4DX) ) has provided an announcement.
4DMedical has defended the adequacy of its disclosures to the ASX regarding its expanded agreement with Stanford University and additional hospital deployments in Brazil, arguing that the strategic significance of these deals lies in advancing its commercialisation strategy rather than in immediate financial metrics. The company said the Stanford expansion, which adds pay-per-scan access to CT:VQ™ without guaranteed scan volumes, is material because it establishes a reference site at a top-tier US academic medical centre and is expected to support revenue growth over time, while revenue to date from both Stanford and five Brazilian hospitals remains immaterial and terms are limited to initial 12‑month periods.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is an Australian medical technology company specialising in advanced lung imaging and analysis, with a key product CT:VQ™, which has received FDA approval. The company’s commercial strategy is centred on penetrating the US market by deploying its technology at leading academic medical centres and key opinion leader sites, complemented by expansion into selected international hospitals to drive clinical adoption and reimbursement-backed usage of its diagnostic imaging solutions.
Average Trading Volume: 5,480,501
Technical Sentiment Signal: Buy
Current Market Cap: A$2.02B
For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.